Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01211652
First received: September 20, 2010
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to assess in general population NSAID and gastroprotective agent utilization and compliance in elderly people.


Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • NSAID Treatment Compliance [ Time Frame: At the end of month 1 ] [ Designated as safety issue: No ]
  • Gastroprotective agent compliance (Girerd Questionnaire) [ Time Frame: At the end of month 1 ] [ Designated as safety issue: No ]

Enrollment: 8186
Study Start Date: October 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Community sample

Criteria

Inclusion Criteria:

  • French people > 65 years old, part of Kantar Health Access Santé panel
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01211652

  Show 3511 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Dr Jean-Francois Bretagne Service gastro-enterologie et hepatologie CHRU Pontchaillou 35033 RENNES cedex France
Study Chair: Pr Gerard Thiefin Service Hepato-Gastroenterologie CHU Reims 51092 REIMS cedex France
Principal Investigator: Mrs Genevieve BONNELYE KantarHealth - France138, avenue Marx Dormoy 92120 Montrouge cedex
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01211652     History of Changes
Other Study ID Numbers: NIS-PFR-DUM-2010/1
Study First Received: September 20, 2010
Last Updated: January 28, 2013
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Compliance
France
Self-administered questionnaire to patients

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Therapeutic Uses
Pharmacologic Actions
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on September 22, 2014